Teva Pharmaceutical Industries Limited ( (TEVA) ) has released its Q1 earnings. Here is a breakdown of the information Teva Pharmaceutical Industries Limited presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teva Pharmaceutical Industries Limited is a global biopharmaceutical company known for its extensive range of generic and innovative medicines, operating across various markets worldwide. In its first quarter of 2025, Teva reported its ninth consecutive quarter of revenue growth, with total revenues reaching $3.9 billion, marking a 5% increase in local currency terms compared to the previous year. The company’s innovative medicines, including AUSTEDO, AJOVY, and UZEDY, demonstrated strong performance, contributing significantly to the revenue growth. AUSTEDO alone saw a 39% increase in revenues, while AJOVY and UZEDY also showed substantial growth. Teva’s generics business also performed well, with growth across all regions. The company is progressing with its Pivot to Growth strategy, aiming for a 30% operating profit margin by 2027, and has announced targeted programs to achieve $700 million in net savings. Looking ahead, Teva remains focused on transforming into a modern biopharmaceutical company, with a clear roadmap to accelerate growth and optimize operations, while maintaining a strong commitment to innovation and generics.